BACKGROUND: Castleman´s disease is an extremely rare heterogenous lymphoproliferative pathology with a mostly benign behavior. It is a localized or generalized lymph node enlargement of an unknown aetiology. Unicentric form is typically a slow-growing solitary mass occurring mostly in the mediastinum, abdominal cavity, retroperitoneum, pelvis and neck. Aetiology and pathogenesis of CD is probably diverse, varying in different types of this heterogeneous disease. MATERIALS AND METHODS: Authors present a review of this issue based on their extensive experience. The aim is to summarize the crucial factors in the management of diagnostics and a surgical treatment of the unicentric form of Castleman´s disease. One of the key issues in the unicentric form is precise preoperative diagnostics and thus choosing the right surgical treatment strategy. Authors highlight pitfalls of the diagnosis and surgical treatment. RESULTS: All histological types such as a hyaline vascular type, plasmacytic type and a mixed type are presented as well as options of surgical and conservative treatment. Differential diagnosis and malignant potential is discussed. CONCLUSION: Patients with Castleman´s disease should be treated in the high- volume centers, with a great experience in major surgical procedures as well as with preoperative imaging diagnostic techniques. Specialized pathologists and oncologists focusing on this issue are also absolutely necessary to avoid misdiagnosis. Only this complex approach can lead to excellent outcomes in patients with UCD.

Department of Hematology and Oncology University Hospital in Pilsen Plzen Czechia

Department of Imaging Methods Faculty of Medicine in Pilsen Charles University Pilsen Czechia

Department of Surgery Faculty of Medicine in Pilsen Charles University Pilsen Czechia

Faculty of Medicine in Pilsen Charles University Plzen Czechia

Zobrazit více v PubMed

Castleman B, Iverson L, Menendez V. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer (1956) 9(4):822–30. doi: 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4 PubMed DOI

Sawaya Z, Semaan DB, Nicolas G, Dib A, Tayar C. Unicentric castleman's disease: Laparoscopic approach of a para-duodenal retroperitoneal mass. Am J Case Rep (2020) 21:e918444. doi: 10.12659/AJCR.918444 PubMed DOI PMC

Dispenzieri A, Fajgenbaum DC. Overview of castleman disease. Blood (2020) 135(16):1353–64. doi: 10.1182/blood.2019000931 PubMed DOI

Roca B. Castleman's disease. A review. AIDS Rev (2009) 11(1):3–7. PubMed

Wong RSM. Unicentric castleman disease. Hematol Oncol Clin North Am (2018) 32(1):65–73. doi: 10.1016/j.hoc.2017.09.006 PubMed DOI

Mitsos S, Stamatopoulos A, Patrini D, George RS, Lawrence DR, Panagiotopoulos N. The role of surgical resection in unicentric castleman's disease: A systematic review. Adv Respir Med (2018) 86(1):36–43. doi: 10.5603/ARM.2018.0008 PubMed DOI

Boutboul D, Fadlallah J, Chawki S, Fieschi C, Malphettes M, Dossier A, et al. . Treatment and outcome of unicentric castleman disease: A retrospective analysis of 71 cases. Br J Haematol (2019) 186(2):269–73. doi: 10.1111/bjh.15921 PubMed DOI

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. . The full spectrum of castleman disease: 273 patients studied over 20 years. Br J Haematol (2018) 180(2):206–16. doi: 10.1111/bjh.15019 PubMed DOI

van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, et al. . International evidence-based consensus diagnostic and treatment guidelines for unicentric castleman disease. Blood Adv (2020) 4(23):6039–50. doi: 10.1182/bloodadvances.2020003334 PubMed DOI PMC

Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for castleman disease. Leuk Lymphoma (2015) 56(5):1252–60. doi: 10.3109/10428194.2014.953145 PubMed DOI

Simpson D. Epidemiology of castleman disease. Hematol Oncol Clin North Am (2018) 32(1):1–10. doi: 10.1016/j.hoc.2017.09.001 PubMed DOI

Fayand A, Boutboul D, Galicier L, Kahn JE, Buob D, Boffa JJ, et al. . Epidemiology of castleman disease associated with AA amyloidosis: Description of 2 new cases and literature review. Amyloid (2019) 26(4):197–202. doi: 10.1080/13506129.2019.1641078 PubMed DOI

Talat N, Belgaumkar AP, Schulte KM. Surgery in castleman's disease: A systematic review of 404 published cases. Ann Surg (2012) 255(4):677–84. doi: 10.1097/SLA.0b013e318249dcdc PubMed DOI

Talat N, Schulte KM. Castleman's disease: Systematic analysis of 416 patients from the literature. Oncologist (2011) 16(9):1316–24. doi: 10.1634/theoncologist.2011-0075 PubMed DOI PMC

Bracale U, Pacelli F, Milone M, Bracale UM, Sodo M, Merola G, et al. . Laparoscopic treatment of abdominal unicentric castleman's disease: A case report and literature review. BMC Surg (2017) 17(1):38. doi: 10.1186/s12893-017-0238-6 PubMed DOI PMC

Dispenzieri A, Armitage JO, Loes MJ, Geyer SM, Alfred J, Camoriano JK, et al. . The clinical spectrum of castleman´s disease. Amer J Hematol (2012) 87:997–1002. doi: 10.1002/ajh.23291 PubMed DOI PMC

Sbrana F, Zhou D, Zamfirova I, Leonardi N. Castleman's disease: A rare presentation in a retroperitoneal accessory spleen, treated with a minimally invasive robotic approach. J Surg Case Rep (2017) 2017(10):rjx195. doi: 10.1093/jscr/rjx195 PubMed DOI PMC

Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am (2018) 32(1):11–21. doi: 10.1016/j.hoc.2017.09.002 PubMed DOI

Available at: https://cdcn.org/clinical-guidance/.